A smart amphiphilic nanoplatform amplifies ROS-mediated immunogenic cell death to suppress bladder cancer growth and metastasis Authors: Chuntao Li, Fanhu Meng, Chunbo Lu, Aimei Li, Ziru Liu, Jin Liu, Hong Zhang, Zhengqiang Yang, Jingkun Bai Published: 2025 ABSTRACT AbstractBladder cancer (BC) remains a prevalent urothelial malignancy characterized by high recurrence and mortality rates, severely compromising patients’ quality of life. Current intravesical chemotherapies, although locally administered, are limited by rapid renal excretion and poor tumor accumulation, which undermines treatment efficacy. Moreover, these conventional agents often cause immunosuppression, further diminishing therapeutic outcomes. To address these challenges, we developed MC/Pep, an innovative amphiphilic peptide-based nanoplatform that self-assembles into spherical nanoparticles capable of codelivering mitoxantrone (MT) and cinnamaldehyde (CA). A key innovative feature of this system is its matrix metalloproteinase 2 (MMP2)-responsive structural transformation, which triggers morphological rearrangement into highly aggregated nanostructures within the tumor microenvironment, enabling enhanced targeted accumulation and retention. In addition to improving drug delivery, MC/Pep induced endoplasmic reticulum oxidative stress-mediated immunogenic cell death (ICD) through the triggering of reactive oxygen species (ROS) generation via intracellular redox reactions. MC/Pep also promoted the production of mitochondria-derived ROS by inducing changes in mitochondrial membrane permeability, thereby synergistically enhancing the ICD effect. This system induced the ectopic displacement of calreticulin (CRT) and the exocytosis of high-mobility group protein B1 (HMGB1) and facilitated DC maturation and T-cell activation in vivo, thereby eliciting an antitumor immune response. Owing to its promising pharmacokinetic properties, tumor-targeting ability, and ability to enhance both immunomodulation and drug accumulation, MC/Pep represents a novel and clinically promising nanotherapeutic strategy for BC, offering a viable path toward translation in immunotherapy-enhanced chemotherapy.Graphical Abstract Schematic illustration of the therapeutic and immunogenic cascade mediated by the enzyme-responsive MC/Pep delivery system in breast cancer Supplementary InformationThe online version contains supplementary material available at 10.1186/s12951-025-03935-5.Keywords: Peptide self-assembly, Enzyme response, Shape shifting, Immunogenic cell death, Reactive oxygen species Introduction Bladder cancer (BC) is the most common malignancy of the urinary system and is among the most prevalent malignancies worldwide, the complexity of which is multidimensional with respect to its pathological features and therapeutic barriers [1–3]. Drug efficacy in bladder cancer faces two major barriers: (1) dense tumor stroma and urinary flushing, which impedes drug penetration and retention [4, 5], and (2) rapid renal excretion, which hinders the maintenance of therapeutic intratumoral drug concentrations [6]. Although nanotechnology has improved drug distribution properties through enhanced permeation and retention (EPR) effects, passive targeting mechanisms still have fundamental limitations with respect to penetrating the tumor mesenchymal barrier, resulting in insufficient drug accumulation in the core tumor region [7]. In the treatment of brain tumors and lung metastases, researchers have employed convection-enhanced delivery technology to administer core therapeutic components to brain tumor regions, addressing critical challenges such as the blood-brain barrier (BBB) impedance of drug delivery and insufficient T-cell infiltration, thereby successfully inhibiting tumor growth [8–11]. Notably, existing studies on the design of tumor microenvironment-responsive delivery systems have generally adopted a single “rupture-is-terminal” drug release strategy, neglecting the dynamic regulation of subsequent drug efflux [12, 13]. Therefore, the key to advancing BC treatment is improving systems for delivering drugs. Conventional therapies, such as chemotherapy and radiotherapy, may lead to systemic immunosuppression and reduce the efficacy of therapy [14]. Monocytes inhibit CD8 + T-cell function through their own PD-L1, leading to immune system evasion [15]. Although immune checkpoint inhibitors can improve the tumor immune microenvironment, some patients do not benefit from them, owing to the complexity of the tumor microenvironment [16]. Immune cell death (ICD) has also shown great potential in the field of BC treatment. Immune cell death (ICD) also shows tremendous potential in breast cancer therapy. In immunogenic cell death, calreticulin translocation serves as a critical “eat me” signal because it triggers antitumor immune responses by stimulating both innate and adaptive immune reactions [17, 18]. Mitoxantrone (MT) interferes with DNA synthesis and repair, inducing apoptosis in tumor cells and causing ICD [19, 20]. Cinnamaldehyde (CA) has been shown to induce intracellular ROS generation [21]. The generation of ROS has been proposed to further induce ICD [22]. Matrix metalloproteinase 2 (MMP2) expression is upregulated in the complex tumor microenvironment of BC [23]. Peptide drug-carrying systems can be catabolized to release drugs upon MMP2 induction. We designed the MMP2 enzyme-responsive amphiphilic peptide Pep, which contains an RGD sequence, is capable of actively targeting tumor cells and can simultaneously undergo deformation in response to MMP2 to increase drug accumulation in the tumor microenvironment [24, 25]. MC/Pep, an MT/CA-loaded Pep system, induces oxidative stress in the endoplasmic reticulum through the production of intracellular reactive oxygen species (ROS) and simultaneously increases mitochondrial ROS levels by altering mitochondrial membrane permeability. These mechanisms work together to cause the ectopic presentation of calreticulin (CRT) on the plasma membrane and the exocytosis of high-mobility group box protein B1 (HMGB1). These damage-associated molecular patterns (DAMPs) activate dendritic cell (DC) maturation, thereby priming CD4+/CD8+T cells to secrete proinflammatory cytokines (TNF-α). This immunochemotherapeutic synergy ultimately inhibits the growth and metastasis of BC (Fig. 1). Schematic illustration of the therapeutic and immunogenic cascade mediated by the enzyme-responsive MC/Pep delivery system in breast cancer. MMP2 activation triggers structural transformation of MC/Pep, leading to the release of MT and CA. This process initiates a cascade by increasing the level of intracellular ROS, which induces immunogenic cell death (ICD) characterized by HMGB1 secretion and CRT exposure. These damage-associated signals synergistically activate dendritic cells and promote TNF-α production by CD4+/CD8+T cells. Furthermore, ROS trigger endoplasmic reticulum stress, leading to the upregulation of CHOP expression mediated by XBP1. Together, these cascades synergize to enhance antitumor immunity Results Characterization and toxicity of amphiphilic peptides Pep and Pep0, which are amphiphilic peptides, were designed and synthesized. Pep, which has an RGD motif and is responsive to MMP2, served as the experimental peptide [26]. Pep0, which lacks active targeting ability and MMP2 responsiveness, served as the control peptide (Supplementary Figs. 1–2). The MS results revealed that Pep and Pep0 were successfully synthesized (Supplementary Figs. 3–4). Pep and Pep0 could be used for subsequent experiments. The morphologies of the amphiphilic peptides were examined through TEM, which revealed that the drug-loaded peptides organized themselves into uniformly distributed spherical shapes both before and after drug loading. MC/Pep transformed the spherical particles into aggregates with an irregular structure upon the addition of MMP2. After the addition of MMP2, MC/Pep0 retained its spherical morphology (Fig. 2A). Examination of the particle sizes of the peptides and the drug-carrying peptides revealed no significant changes in size (Supplementary Figs. 5–9). Physicochemical properties and physiological toxicity of Pep and Pep0. (A) TEM images depicting the responses of Pep, MC/Pep, Pep0 and MC/Pep0 following coincubation with MMP2. Scale bar: 100 nm. Zeta potentials of (B) Pep, MC/Pep, (C) Pep0 and MC/Pep0. (D) Cumulative release rates of MT and (E) CA from Pep in the presence or absence of MMP2. (F) Survival rates of NIH 3T3 cells and (G) MB49 cells after 12 h and 24 h of incubation with Pep and Pep0. NS, P > 0.05. * P < 0.05 The potential of the amphiphilic peptides before and after drug loading was additionally examined by Malvern potentiometry. Both Pep and Pep0 had negative potentials before drug loading, and both changed to positive potentials after the drug was encapsulated (Fig. 2B–C). The success of the system may be due to the successful assembly of peptide‒drug nanocomplexes dominated by hydrophobic interactions [27–29]. Further examination of drug release from Pep upon enzyme induction was performed, and Pep without added MMP2 was used as the control. At 72 h, the rate of MT release in the experimental group was 70.3%, whereas it was 29.9% in the control group (Fig. 2D). Moreover, the cumulative release of CA at 72 h after MC/Pep was added to MMP2 was 72.7%, whereas the cumulative release rate in the group without MMP2 was only 32.5% (Fig. 2E). The drug release profiles of MT and CA were modestly affected by the presence of 10% serum or a pH of 6.8 (Supplementary Figs. 10–11). The release of the drug from Pep was attributed to a morphological transformation induced by MMP2. These findings indicate that under physiological conditions, drug-loaded peptides exhibit reduced release of the drug, potentially minimizing toxic side effects on nontargeted organs. In tumor tissues, the drug-carrying peptide reacts with MMP2 to release antitumor drugs, thereby inhibiting tumor growth. The amphiphilic peptides were incubated with mouse embryonic NIH 3T3 fibroblasts, MB49 cells and SV-HUC-1 cells. Next, a CCK-8 assay was performed to determine cell proliferation. The viability of the NIH 3T3 cells was unchanged at 12 h (Fig. 2F). The viability of the SV-HUC-1 cells was virtually unchanged at 12 h and 24 h (Supplementary Figs. 12–13). Compared with the control groups, the Pep group showed a reduction in the survival of the MB49 cell line. Extending the incubation period to 24 h further decreased the survival rate of the MB49 cells (Fig. 2G). The cytotoxic effect of Pep on MB49 cells gradually increased over time. HPLC was used to analyze the enzymatic products of the peptides and explore the mechanism of the morphological transformation of Pep. HPLC analysis revealed that Pep showed absorbance peaks at 15.4 min and that new product peaks appeared 7.6 min and 19.2 min after the addition of MMP2 at 96 h. Pep0 did not display any new product peaks after MMP2 was introduced (Supplementary Figs. 14–17). HPLC and MS results indicated that Pep was responsive to MMP2, enabling the production of new products catalyzed by MMP2 (Supplementary Fig. 18). The MMP2 enzyme triggered the exposure of the hydrophobic structure of the Pep substrate through specific cleavage, which in turn drove a shift in its self-assembled morphology [14, 30, 31]. Tumor cells overexpressing MMP2 catalyze the transformation of Pep into irregular aggregated structures with membrane-disrupting ability. Cellular uptake and intracellular retention of drug-loaded peptides Amphiphilic peptide uptake was investigated by confocal laser scanning microscopy (CLSM). By replacing the MC with coumarin 6 (C6), the drug peptides were fluorescently labeled. CLSM was used to observe the fluorescence distribution of C6, C6/Pep0 or C6/Pep after an incubation with cells for a specific period. After 0.25 h, weak green fluorescence was detected in the MB49 cells, which was slightly more evident in the C6/Pep group (Fig. 3A). When the incubation time was prolonged to 2 h, the uptake of the drug by the cells increased. In the C6 group, the fluorescence was still weak. In the MB49 cells, incubation with C6/Pep resulted in significant green fluorescence, which was far more noticeable than that in the C6/Pep0 group (Fig. 3B). Quantification of the uptake results at 0.25 h and 2 h revealed that the rate of Pep uptake was 2.1 times higher than that of Pep0 at both time points (Supplementary Figs. 19–20). Moreover, we explored the uptake of drug-carrying peptides by MB49 cells via flow cytometry. The results revealed that the drug uptake rate was significantly greater in the C6/Pep group (Fig. 3C-F). A 3D microsphere model of the tumor was subsequently used to determine the depth of Pep penetration into the tumor, and the results revealed that the fluorescence intensity of the C6/Pep group was greater than that of the other two groups (Supplementary Fig. 21). The above experiments showed that Pep enhances the uptake of the drug by cells, which might be connected to its tumor-targeting properties. Intracellular intake and retention of C6-containing peptides. (A) CLSM images showing MB49 cells incubated for 0.25 h with C6, C6/Pep0, or C6/Pep. (B) CLSM images showing MB49 cells incubated for 2 h with C6, C6/Pep0, or C6/Pep. Scale bar: 50 μm. (C) FCM analysis of MB49 cells after coincubation for 0.25 h. (D) FCM fluorescence quantification of cellular uptake by MB49 cells after 0.25 h. ***P < 0.001. (E) FCM analysis of MB49 cells after 2 h of coincubation. (F) FCM fluorescence quantification of cellular uptake by MB49 cells after 2 h. ***P < 0.001. (G) CLSM images of MB49 cells incubated with C6, C6/Pep0 or C6/Pep for 96 h. (H) CLSM images of MB49 cells incubated with C6, C6/Pep0 or C6/Pep for 120 h. Scale bar: 50 μm We further examined the retention of various drug formulations within MB49 cells. The cells were treated with C6, C6/Pep0, or C6/Pep for 2 h, incubated with fresh medium for 96–120 h, and then analyzed using CLSM. MB49 cells cocultured with C6 displayed almost no fluorescence after 96 h and 120 h. A large amount of green fluorescence was observed in MB49 cells cocultured with C6/Pep0 and C6/Pep. The intracellular fluorescence intensity in the C6/Pep group was 2.7 and 1.7 times greater than that in the C6/Pep0 group at 96 h and 120 h, respectively (Fig. 3G-H, Supplementary Figs. 22–23). Additionally, the retention of drug-loaded peptides in MB49 cells was investigated via flow cytometry. The results revealed that the drug content in the C6/Pep group was greater than that in the C6/Pep0 group, which was consistent with observations from CLSM (Supplementary Figs. 24–27). Pep extended the retention time of the drug in MB49 cells, potentially due to the morphological changes of the drug-carrying peptide when MMP2 was present. Effects of MC/Pep on the migration and ROS-generating capacity of MB49 cells Inhibiting the migration of tumor cells is important for cancer therapy. Scratch wound healing assays were performed with MB49 cells. Compared with that in the other groups, the migratory capacity of MB49 cells in the MC/Pep group markedly decreased (Fig. 4A). After 48 h, the inhibitory effect of MC/Pep on MB49 cell migration was 2-fold greater than that of MC/Pep0 (Fig. 4B). Influence of drug-carrying peptides on MB49 cell migration, apoptosis and ROS levels. (A) Images of migrating MB49 cells after incubation with HEPES, MT, MC, MC/Pep0, or MC/Pep for 24–48 h. Scale bar: 200 μm. (B) Associated quantitative analysis of the cell area. ***P < 0.001. (C) MB49 cells were incubated with HEPES, MT, MC, MC/Pep0, or MC/Pep, and apoptosis was assessed by flow cytometry. (D) CLSM images of ROS levels in MB49 cells incubated with HEPES, MT, MC, MC/Pep0, or MC/Pep for 24 h. Scale bar: 50 μm The level of MB49 apoptosis after treatment with different preparations was assessed using an Annexin V-FITC apoptosis kit (apoptosis rate: Q2 + Q3). After the MT, MC, MC/Pep0 and MC/Pep treatments, the percentages of late apoptotic MB49 cells detected by flow cytometry were 4.2%, 17.5%, 29.5%, and 70.8%, respectively (Fig. 4C). Repeated experiments confirmed that the MC/Pep group differed from the other groups and that MC/Pep was the most efficient at inducing apoptosis in MB49 cells. The chemotherapeutic drug MT induces ROS production by binding to mitochondria to induce ICD [32, 33]. CA further induces ROS production and leads to apoptosis [34]. The findings of this study indicated that MC/Pep effectively inhibited the migration and promoted the apoptosis of MB49 cells. ICD is a distinct form of cell death that increases immune cell infiltration and alters the tumor microenvironment for tumor elimination [35–37]. In vivo, ICD is connected to both ROS levels and damage-associated molecular patterns (DAMPs). DAMPs involve the exposure of CRT on the cell membrane and the release of high mobility group protein (HMGB1) [38, 39]. These DAMPs initiate and promote the maturation process of DCs. Mature DCs expose antigens and eventually recruit cytotoxic T lymphocytes (CTLs) into tumors to kill tumor cells [37, 40, 41]. ROS are potent inducers of ICD, and they disrupt the equilibrium between the protein folding load and volume, leading to increased endoplasmic reticulum pressure [42, 43]. The DCFH-DA ROS probe itself is nonfluorescent. When ROS enter the cell, intracellular esterases oxidize DCFH-DA to DCFH, which cannot penetrate the cell membrane, thus causing DCFH to remain inside the cell. ROS further oxidize DCFH to DCF and emit green fluorescence [44, 45]. Compared with those in the other groups, the cells in the MC/Pep group presented greater green fluorescence, indicating that many cytotoxic ROS were produced in the cells (Fig. 4D). In the other groups, the fluorescence intensity of the cells decreased. A quantitative fluorescence assay revealed that the ROS content in the MC/Pep group was 1.5 times greater than that in the MC/Pep0 group (Supplementary Fig. 28). The combination of MT and CA treatments appears to cause increased ROS levels in cancer cells. Second, alterations in the mitochondrial membrane potential in MB49 cells treated with various drugs were assessed using a JC-1 kit. The green fluorescence intensity of the MC/Pep group was 1.6 times that of the MC/Pep group (Supplementary Fig. 29). These results indicate that MC/Pep can significantly affect the mitochondrial membrane potential and alter its permeability. Through the RGD sequence of Pep, MC/Pep is concentrated at the tumor site and reacts with MMP2 to release MC. MT induces ROS production by binding to mitochondria to induce ICD, and CA further induces ROS production. Effects of MC/Pep on HMGB1 and CRT generation and the induction of DC maturation in MB49 cells Increased levels of ROS within tumor cells accelerate the release of HMGB1 into the extracellular space [46]. Previous experiments have demonstrated that drug-carrying peptides increase ROS levels and are expected to further facilitate the release of HMGB1 into the extracellular environment. HMGB1 expression in cells treated with drug-loaded peptides was detected by immunofluorescence staining. The release of HMGB1 into the extracellular matrix increased in the MC/Pep group (Fig. 5A). Fluorescence quantification revealed that the fluorescence intensity of MC/Pep0 was 2.0 times greater than that of MC/Pep (Supplementary Fig. 30). These findings suggested that the drug-carrying peptide induces ICD in MB49 cells and is superior to the free drug and MC/Pep0. Effects of drug-loaded peptides on HMGB1 and CRT generation and the induction of DC maturation in MB49 cells. (A) Fluorescence microscopy images of HMGB1 expression in MB49 cells incubated with HEPES, MT, MC, MC/Pep0, or MC/Pep for 24 h. (B) CLSM images of CRT in MB49 cells following a 24 h incubation with HEPES, MT, MC, MC/Pep0 or MC/Pep. (C) In vitro maturation analysis of BMDCs. Scale bar: 50 μm CRT exposure triggers DCs to phagocytose released antigens, thereby initiating the tumor immune cycle [47–49]. CLSM images revealed that the MT group had minimal levels of exposure to CRT, whereas the MC/Pep-treated group had the strongest intensity of red fluorescence (Fig. 5B). Fluorescence quantitative analysis revealed that the CRT content in the MC/Pep group was approximately 2.5 times that in the MC/Pep0 group (Supplementary Fig. 31). These findings suggest that MC/Pep significantly promotes the induction of heterotopic CRT. Compared with the control treatment, MC/Pep treatment significantly increased the efficiency of ICD by markedly increasing the expression levels of CRT and HMGB1, thereby promoting dendritic cell maturation and initiating antitumor immune responses. The ICD effect was mimicked in vitro by adding mouse myeloid dendritic cells (BMDCs) to the lower chamber and inoculating MB49 cells into the upper chamber. After 24 h of incubation, the maturation rate of BMDCs in the MC/Pep group was 45.8% (Fig. 5C), which was higher than that in the MC/Pep0 group (20.9%). These findings suggest that MB49 cells treated with MC/Pep release substantial quantities of tumor-associated antigens, thereby facilitating the maturation of BMDCs. ROS in tumor cells can activate endoplasmic reticulum stress pathways. We detected the levels of GRP78, XBP1s and CHOP by Western blotting. The results revealed that the levels of the three proteins increased (Supplementary Fig. 32). This change may have occurred because the IRE1 pathway is activated when misfolded proteins bind to GRP78 [50]. The mRNA precursor of XBP1 is cleaved by IRE1 in the endoplasmic reticulum lumen, leading to the generation of active XBP1s [51]. XBP1s increases the expression of CHOP by entering the nucleus [52]. DCs initiate innate and antigen-specific immune system responses [53–56]. DCs present tumor-associated antigens and stimulate T-cell responses, thereby significantly enhancing immune function. As immature DCs undergo maturation, the cell surface increasingly expresses CD80 and CD86 [57–61]. The successful induction of an antitumor T-cell immune response depends on the maturation of differentiated DCs. CD80 and CD86 have been recognized as markers of DC maturation [62, 63]. In the present study, BMDCs were cocultured with MB49 cells treated by different methods, and the results were detected by flow cytometry. Compared with the other groups, MC/Pep increased the levels of CD80 and CD86 expression and induced the greatest increase in immunogenicity. In particular, compared with nondeformable drug-carrying peptides, MC/Pep led to more efficient tumor antigen presentation. Distribution of MC/Pep in vivo To detect the targeting of drug-carrying peptides in vivo, drug carriers were prepared using DiR fluorescent dye instead of drugs for fluorescence imaging (Fig. 6A). Using small animal in vivo imaging, significant fluorescence was observed in the DiR/Pep group of mice and tumors after 72 h (Fig. 6B). DiR/Pep had the strongest accumulation and retention in the tumor region. The organs were collected after 72 h, after which the fluorescence signals were detected. The group of tumors with the highest fluorescence intensity was DiR/Pep. The fluorescence intensity of the DiR/Pep group was 2.1 times greater than that of the DiR/Pep0 group (Fig. 6C-D). These findings demonstrated that the designed peptides have good targeting ability and stability in complex physiological environments. Frozen tumor sections were prepared to observe the DiR fluorescence intensity by fluorescence microscopy. Compared with DiR/Pep0, DiR/Pep had a significantly greater fluorescence intensity in the tumor (Fig. 6E-F). These findings indicated that Pep is effectively targeted and accumulates at the tumor site for extended functional time. In vivo imaging of mice. (A) Schematic diagram of drug administration. (B) Fluorescence intensity in the mice at specific times. (C) Fluorescence images of the tumors and major organs after drug administration at 72 h. (D) Quantitative fluorescence analysis. ***P < 0.001. (E) Images of frozen mouse tumor sections. Scale bar: 200 μm. (F) Quantitative fluorescence analysis of the distance from the tumor edge to the interior In vivo antitumor activity of MC/Pep A subcutaneous tumor model was established by injecting MB49 bladder cancer cells under the skin to investigate the antitumor effects of MC/Pep in vivo. The tumor-bearing mice were treated a total of 7 times (Fig. 7A). Compared with the other groups, the MC/Pep group of mice exhibited the best tumor suppression effect. Compared with those in the saline group and other treatment groups, the tumor size in the MC/Pep group was much smaller (Fig. 7B). MC/Pep had the best antitumor effect and the highest tumor control rate of approximately 88% (Fig. 7C-E). This phenomenon may be related to the ability of RGD sequence-containing peptides to target the interior of the tumor and the ability of the peptides to deform in response to induction by MMP2 to enhance drug retention. In addition, little change in weight was observed in any of the groups (Fig. 7F). In vivo antitumor effects. (A) Schematic diagram of drug administration in vivo. (B) Images of subcutaneous tumors in mice. (C) Quantitative map of subcutaneous tumor weights in mice. *P < 0.05; ***P < 0.001. (D) Curves showing changes in tumor volume. ***P < 0.001. (E) Tumor suppression rate. *P < 0.05; ***P < 0.001. (F) Mouse body weights. (G) DC maturation in vivo. (H) H&E staining for tumor histopathology and TUNEL staining for identifying apoptotic tumor cells. Scale bar: 100 μm Mature dendritic cells initiate the immune response by presenting tumor antigens to T cells. Therefore, we used a flow assay to detect MC/Pep-induced DC maturation in mice in vivo, which revealed that MC/Pep increased the proportion of mature DCs to 26.7% in mice (Fig. 7G). MC/Pep treatment significantly induced DC maturation, which may be attributed to MT inducing ICD by increasing the intracellular ROS content through redox reactions. ROS activate several signaling pathways in dendritic cells and promote DC maturation in vivo. During this process, DCs undergo numerous changes, including significant upregulation of CD80 and CD86 expression. Mature DCs are capable of inducing T-cell activation, proliferation, and differentiation [41, 57, 64, 65]. T cells secrete immune factors (TNF-α) into the tumor site to achieve antitumor effects [66–68]. After antitumor testing, tumors were detected using H&E and TUNEL staining (Fig. 7H). H&E staining revealed no major abnormalities in the heart, liver, spleen, or kidney of each group in the antitumor experiments. In vivo antitumor experiments indicated that MC/Pep did not cause toxicity to other major internal organs. Compared with the other treatments, MC/Pep treatment ameliorated the destruction of the alveolar structure in lung tissue sections (Supplementary Fig. 33). The immunohistochemistry results revealed lower CD25 expression in the MC/Pep group than in the MC/Pep0 and saline groups. TNF-α expression was higher in the MC/Pep group than in the MC/Pep0 group or in the other subgroups (Supplementary Fig. 34). The tumor cells from the saline group had a higher level of heterogeneity and greater nucleoplasmic ratios, indicating a lower degree of differentiation and a poorer prognosis. Tumors from the MC/Pep group displayed a notably greater number of necrotic areas (Fig. 7H). CD4, CD8, CRT, CD45RO, CD56 and TNF-α expression in mouse tumor tissue sections was assessed via immunofluorescence staining. Immunofluorescence staining for CD4, CD8, and CRT in tumor tissue was significantly greater in mice treated with MC/Pep than in those in the other subgroups (Fig. 8A-C, Supplementary Figs. 35–37). Immunofluorescence staining revealed that the CD45RO, CD56, and TNF-α levels in tumor tissues from the MC/Pep treatment group were 1.8, 1.9, and 1.5 times greater than those in the MC/Pep0 treatment group, respectively (Supplementary Figs. 38–40). The increase in CD4 and CD8 expression may be attributed to MC/Pep increasing ICD in mice and inducing DC maturation. Mature DCs promote T-cell differentiation, leading to increases in CD4 and CD8 levels [69–71]. The observed increase in CRT fluorescence intensity may be attributed to the induction of ICD by MC/Pep, which induced the transfer of CRT from the inside to the outside. MC/Pep is effective at eliciting ICD and enhancing the maturation of DCs and differentiation of T cells in a living system. (A) CD4, (B) CD8, and (C) CRT immunofluorescence in an in vivo antitumor assay. Scale bar: 100 μm In vivo antimetastatic effect of MC/Pep We next tested the antimetastatic effects of these treatments in vivo. A tail vein injection of tumor cells was used to model lung metastasis. After the mice were euthanized, their lungs and other organs containing metastases were dissected and subjected to histological processing. The MC/Pep group had a notably lower number of metastatic nodules (Fig. 9A-B), which indicated that MC/Pep treatment clearly inhibited lung metastasis in the mice. The body weight of each subgroup of mice did not significantly change during lung metastasis treatment (Fig. 9C). In vivo antimetastatic effects. (A) Representative pictures of lung metastases in mice. (B) Quantitative analysis of lung nodules in mice. ***P < 0.001. (C) Body weights of the mice. (D) Mouse lung sections. (E) TNF-α assay in the lungs. Scale bar: 100 μm The organs of the mice with lung metastasis were analyzed histochemically by H&E staining. Compared with the MC/Pep group, the saline group exhibited larger metastatic nodules in the lung sections (Fig. 9D), which suggested that MC/Pep effectively inhibited the lung metastasis of tumor cells in mice. H&E staining revealed no morphological damage to the major organs (Supplementary Fig. 41). Immunohistochemical staining revealed that CD8 expression was greater in the MC/Pep group than in the MC/Pep0 and saline groups (Supplementary Fig. 42). Immunofluorescence staining was performed to detect TNF-α expression in the lungs. Compared with those in the other treatment groups, the fluorescence intensity in the MC/Pep experimental group was notably greater (Fig. 9E). The alveolar structure in the MC/Pep group was distinctly visible in lung sections stained with H&E, showing a regular cystic shape and relatively uniform size. The alveoli in the other groups exhibited dilatation or atrophy. This phenomenon may be due to the infiltration of inflammatory cells and the proliferation of fibrous tissue [72]. The MC/Pep group had a more homogeneous distribution of diffuse tissue in the lung interstitium. These findings indicated that MC/Pep treatment significantly inhibited lung metastasis. Pharmacokinetic assays The distribution of nanodelivery systems in vivo is critical for their ability to be used clinically. Because peptides are easily cleared from the bloodstream by the reticuloendothelial system [73, 74], we examined the tissue distribution and metabolism of the drug in the body by measuring the drug levels in the blood, heart, liver, spleen, lungs, and kidneys. The drug was detected in the blood, and the highest concentration in the blood occurred after the injection. Compared with drug-loaded Pep0, drug-loaded Pep had higher drug retention concentrations (Fig. 10A-B). Detection of drugs in urine and feces revealed that the MT and CA drug concentrations stabilized at 24 h in vivo. In addition, the drug-loaded Pep concentrations were lower than the drug-loaded Pep0 concentrations (Fig. 10C-F). Pharmacokinetic assay. MT and CA in (A-B) blood, (C-D) urine and (E-F) feces, respectively. MT and CA in (G-H) tumors, (I-J) livers and (K-L) kidneys, respectively After injection, drug accumulation at the tumor location increased and stabilized at 48 h. The concentration of drug-loaded Pep at the tumor location exceeded that of drug-loaded Pep0 (Fig. 10G-H). The drug concentration in the organs was the highest at approximately 4 h, and the concentrations decreased over time and were noticeably lower in the drug-loaded Pep group than in the drug-loaded Pep0 group (Fig. 10I-L, Supplementary Fig. 43). The cumulative content of drugs in the MC/Pep group was the lowest in feces and urine, while the content in tumors increased with time. These findings suggest that MC/Pep is effectively enriched in tumor tissues. The induction of ICD using a drug-carrying system offers a method for treating BC. Through the “bystander effect”, the immune system can remove cancer cells. MC/Pep alters the permeability of the mitochondrial membrane and decreases the mitochondrial membrane potential through enrichment of CA, which further induces the generation of ROS and increases ICD [22]. MC/Pep effectively targets tumor locations, and the morphology is altered, which may lead to longer retention of drugs and greater accumulation at tumor locations. Ultimately, MC/Pep productively inhibits the growth and metastasis of BC. Conclusions Here, we constructed an MC/Pep delivery drug system for enhanced immunotherapy. MC/Pep self-assembles to form spherical particles and transforms into a highly aggregated fibrous structure upon catalysis by MMP2, which notably extends the external retention time of the drugs and minimizes their toxic side effects. The delivery system is targeted and enriched in BC tissues, triggering mitochondria-mediated ROS release. Furthermore, by increasing heterotopic CRT exposure and promoting HMGB1 release, MC/Pep drives the maturation of DCs and T-cell revitalization, triggering an antitumor immune response and tumor cell apoptosis. Compared with nondeformable drug-carrying peptides, MC/Pep effectively reduces tumor cell proliferation and inhibits metastasis. In summary, we constructed an enzyme-responsive peptide nanocarrier to synergistically induce ICD to achieve dual inhibition of BC growth and metastasis, thereby providing a reliable therapeutic strategy for BC treatment. Although this study provides new insights into the development of our research center, it is worth noting that no direct comparisons were made with established clinical standards such as intravesical BCG or mitomycin C. Therefore, the clinical efficacy of this approach remains to be evaluated in future clinically relevant settings. Materials and methods Materials C6, MT and CA were purchased from Shanghai Aladdin Biochemical Technology Co., Ltd. (Shanghai China). CCK-8 was purchased from NCM Biotech (Suzhou, China). Regenerated cellulose dialysis membranes (MWCO = 1000 Da) were purchased from YuanYe Biotechnology (Shanghai, China). The CRT primary antibody (1:500) and HMGB1 primary antibody (1:1000) were obtained from Beyotime (Shanghai China). Fetal bovine serum (FBS) was purchased from Gibco (NY, USA). The FITC-conjugated goat anti-mouse IgG (H + L) secondary antibody, diluted at a ratio of 1:500, and the FITC-conjugated CD80 antibody, diluted at a ratio of 1:50, were purchased from Invitrogen (Shanghai China), and the anti-CD86-APC antibody (1:20) was obtained from BioLegend (Shanghai China). Anti-CD11c-APC (1:80) was purchased from BD Biosciences (CA, USA). The source of the MB49 cells was the American Type Culture Collection (VA, USA). C57BL/6 female mice (18–20 g) were purchased from Pengyue Laboratory Animal Co., Ltd. (Jinan, China). Peptide synthesis and purification QYAOBIO (Chinapeptides Co., Ltd.) synthesized both the experimental peptide (Pep) and the control peptide (Pep0). Preparation of drug-carrying peptides The peptide was solubilized in a 25 mM HEPES buffer solution to achieve a final concentration of 2 mg/mL. Furthermore, 2 mg of the peptide was dissolved in 30 µL of dimethyl sulfoxide buffer containing 0.4 mg of MT and 0.4 mg of CA. Subsequently, 970 µL of HEPES buffer was added to this mixture to prepare a peptide solution containing MT and CA, which was then maintained at room temperature for subsequent use. The drug-loaded peptide solution was incubated with MMP2 (0.1 µg/mL) in the presence of 10 mM CaCl2 and 150 mM NaCl to produce an enzyme-responsive peptide solution. Liquid chromatography, mass spectrometry The peptide solutions were analyzed using reverse-phase high-performance liquid chromatography (RP-HPLC) with a Thermo Fisher Ultra3000 system (Thermo Scientific), both in the presence and absence of the MMP2 enzyme. The molecular weight (Mw) of the peptides was confirmed by mass spectrometry (MS) [75, 76]. Self-assembly and zeta potential of nanocarriers The samples were subjected to 8 min of adsorption on a copper grid and 8 min of staining with uranyl acetate before the peptide nanocarriers were characterized by transmission electron microscopy (TEM; Hitachi, SU8010, Japan). Using TEM images, a particle size distribution histogram was constructed. A Zetasizer Nano ZS90 from Malvern Instruments was utilized to measure the zeta potential. In vitro drug release MT and CA were encapsulated with peptide carriers, and their in vitro drug release behaviors were investigated. Drug-loaded peptides were left at 25 °C for 12 h and then dialyzed for 1 h. Afterward, 0.1 µg/mL of MMP2, 10 mM CaCl2 and 150 mM NaCl were added. A regenerated cellulose dialysis bag [with a molecular weight cutoff (MWCO) of 1000 Da] was placed in 25 mL of PBS in a shaker, and samples were extracted at specific time intervals. The absorption was then measured with a UV spectrophotometer (680 nm and 256 nm), and the peptide solution without MMP2 was used as the control. CCK-8 assay The cytotoxicity of Pep0 and Pep toward MB49 and NIH 3T3 cells was evaluated using a CCK-8 assay. Cells were seeded into the wells of a 96-well plate at 5 × 103 cells per well. After the cells reached confluence, the medium was removed from all the wells. In the experimental groups, 50 µL of serum-free medium and 50 µL of peptide solution (4 mg/mL) were added to each well. The absorbance of the added CCK-8 reagent was measured at 450 nm. Cellular intake Using a confocal laser scanning microscope (CLSM; Nikon A1, Japan), the uptake of various agents into MB49 cells was examined. C6, C6/Pep0 and C6/Pep were added to the MB49 cells, which were then incubated for 0.25 h and 2 h. DAPI staining was applied to the cell nuclei. CLSM was used to image the cells and observe the distributions of various agents in the MB49 cells. After the cells were treated as described above, they were digested with EDTA-free trypsin, and the suspension was centrifuged and resuspended in PBS. The cell suspension was passed through a membrane and then transferred to a glass tube for quantitative analysis using a FACS Aria III flow cytometer (BD Biosciences). Cell retention assay The retention times of various agents in MB49 tumor cells were analyzed by CLSM. MB49 cells were treated with serum-free medium that contained C6-related agents (C6, C6/Pep0, and C6/Pep) and incubated for 2 h. The culture medium was then changed to fresh complete medium, and the cells were incubated for 96 and 120 h. After the cells were incubated with DAPI, the cells were visualized with CLSM. Cell scratch wound healing assay, apoptosis assay and determination of the mitochondrial membrane potential In a six-well plate, the MB49 cells were spread and allowed to grow to nearly 80% confluence. HEPES, MT, MC, MC/Pep0, and MC/Pep were mixed with serum-free medium at a volume of 1/200 and added to the six-well plates. After incubation for 24 h, the scratch gap was recorded and imaged by microscopy. Flow cytometry was used to identify apoptosis according to the instructions of the Annexin V-FITC Apoptosis Detection Kit. The mitochondrial membrane potential of the MB49 cells was detected using a mitochondrial membrane potential assay kit. Detection of ROS, CRT and HMGB1 The cells were incubated for 24 h with a mixture of a 1:200 volume ratio comprising HEPES, MT, MC, MC/Pep0, MC/Pep, and serum-free DMEM. DCFH-DA was diluted 1000-fold and added to each well. The nuclei were stained with DAPI and observed by CLSM. The aforementioned procedure was used to treat the cells with the drug for 24 h. The cells were then incubated with a CRT antibody (1:200) or an HMGB1 polyclonal antibody (1:200) at 4 °C overnight. Next, the cells were labeled with Cy3 (1:500) and FITC-conjugated secondary antibodies (1:500) for 2 h. After the nuclei were stained with DAPI, the cells were observed with an inverted fluorescence microscope and CLSM. In vitro maturation of DCs Mouse bone marrow-derived dendritic cells were obtained from bone marrow harvested from female C57BL/6 mice. MB49 cells were treated with HEPES, MT, MC, MC/Pep0, or MC/Pep for 12 h to induce apoptosis. The BMDCs and MB49 cells were collected and placed into the lower chambers, whereas the MB49 cells were placed into the upper chambers. After 24 h of culture, the BMDCs were collected and stained with anti-CD11c-APC, anti-CD86-FITC, and anti-CD80-FITC antibodies, followed by analysis by flow cytometry. Western blot analysis of GRP78, XBP1, and CHOP levels The cells were incubated for 24 h with a mixture comprising HEPES, MT, MC, MC/Pep0, MC/Pep, and serum-free DMEM at a 1:200 volume ratio. RIPA lysis buffer was used to extract total protein from the cultured cells. SDS-PAGE was performed on 50 mg of protein from each sample, and the proteins were transferred to a PVDF membrane and incubated with primary antibodies against GRP78, XBP1, and CHOP (1:1000), followed by incubation with an HRP-conjugated secondary antibody. In vivo DC maturation experiments At the end of the treatment, the spleen and lymph nodes were collected. The tissues were ground with a tissue grinding rod. Next, the erythrocytes were lysed by the addition of erythrocyte lysis solution and made into a single-cell suspension, which was incubated with 10% goat serum for 30 min. The dendritic cells were analyzed using anti-CD11c-APC, anti-CD86-FITC, and anti-CD80-FITC antibodies. In vivo lung metastasis assay A lung metastasis model was developed via tail vein injection of MB49 cells (1 × 106). The mice were divided into the following 5 groups (n = 6): saline, MT, MC, MC/Pep0, and MC/Pep (5 mg/kg MT and CA). Following 7 injections, the mice were euthanized, and the lung nodules were quantified. H&E staining was used to detect pathological changes in the lung tissue. Immunofluorescence staining was conducted to assess TNF-α levels. CD8 expression was assessed by immunohistochemistry. Drug metabolism in vivo C57BL/6 mice were divided into MC, MC/Pep0 and MC/Pep groups. At specific time points (1 h, 2 h, 4 h, 8 h, 12 h, 24 h, 48 h, and 72 h), blood was collected from each group of mice after sacrifice. Serum drug concentrations were determined using a multifunctional enzyme reader (wavelengths of 680 nm and 256 nm). The major organs of the mice were collected. After saline was added to the tissue samples (each with the same weight), we ground the tissues into a homogenate. The supernatant was centrifuged, and the drug concentration was subsequently measured by multifunctional enzyme labeling. Urine and feces were collected for drug testing. The total volume of urine was recorded, and the feces were placed in a cool, ventilated area to dry. The feces were then weighed, ground into powder, and mixed with DMSO, and the supernatant was assayed using a multifunctional enzyme-labeling instrument. Data analysis All the statistical analyses were performed using Prism 6.0, OriginPro 8.5, and SPSS 25.0 software. The data are presented as the mean ± standard deviation (SD). A P value of less than 0.05 was considered to indicate statistical significance, and a sample size of no less than three was used for all analyses. Depending on the data characteristics, appropriate statistical methods were applied, including one-way ANOVA, repeated-measures ANOVA, two-way ANOVA, or an unpaired t test. Variance analysis was conducted for in vivo experiments, and relevant post hoc tests were performed where necessary to ensure the robustness of the statistical conclusions. Supplementary Information Supplementary Material 1. Author contributions JB conceived of the project. CTL, FM and AL conducted experiments and data analysis. CTL, FM and CBL contributed equally to this work. AL and ZL conducted data analysis. HZ and ZY provided professional suggestions. The manuscript was reviewed and suggestions were provided by CBL and JB. All authors reviewed the manuscript. Funding This work was supported by the Natural Science Foundation of Shandong Province (ZR2024LMB012, ZR2023MC122). Data availability No datasets were generated or analysed during the current study. Declarations Ethics approval and consent to participate This veterinary clinical trial was reviewed and approved by the Animal Welfare and Animal Experimental Ethics Committee of Shandong Second Medical University (approval ID: 2022SDL439). Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Chuntao Li, Fanhu Meng and Chunbo Lu contributed equally to this work. References Associated Data Supplementary Materials Supplementary Material 1. Data Availability Statement No datasets were generated or analysed during the current study.